Genedata Expands Partnership with Boehringer Ingelheim to Digitalize Next Generation Cell Line Development
Genedata Selector deployed to streamline complex cell line development processes
November 7, 2019
Basel, Switzerland
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced an expansion of its collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company, to digitalize and automate complex cell line development processes. As part of this collaboration, Genedata Selector® has been deployed to support the application of next generation sequencing (NGS) in cell line engineering, clone selection and adventitious agent detection workflows.
Many biopharma companies, like Boehringer Ingelheim, are using NGS-based approaches throughout bioprocess development to speed up workflows and create significant cost savings. Genedata Selector harmonizes and automates these NGS-based workflows by providing an integrated data management and analysis platform. Genedata Selector offers all the features required for deployment into regulatory environments in downstream biologics manufacturing.
The centralized approach to global data management provided by Genedata Selector facilitates collaboration among research groups and sites and reduces error-prone exchange of data files. With an easy-to-use interface and enterprise-wide access to experimental data in one secure system, Genedata Selector enables biopharma companies to increase the efficiency of their decision-making processes. For specific applications, such as NGS-based detection of adventitious agents, Genedata Selector also creates the opportunity for biopharma R&D organizations to become independent of external service providers and gain full control of data, resulting in tremendous savings in time and money.
“We are very excited about our partnership with Boehringer Ingelheim, an innovative leader in the biopharma industry,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Genedata is committed to supporting our customers looking to automate and digitalize their bioproduction processes by providing the most advanced and innovative technologies for organizations to maximize their return.”
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
www.genedata.com
LinkedIn | Twitter | YouTube
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Genedata is committed to supporting our customers looking to automate and digitalize their bioproduction processes by providing the most advanced and innovative technologies for organizations to maximize their return